Northern Trust Corp Prometheus Biosciences, Inc. Transaction History

Northern Trust Corp

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$103.46 - $126.29 $981,421 - $1.2 Million	9,486 Added 3.08%	317,526 $34.1 Million
Q4 2022 Feb 13, 2023	BUY	$36.06 - $117.21 $1.67 Million - $5.44 Million	46,438 Added 17.75%	308,040 $33.9 Million
Q3 2022 Nov 14, 2022	BUY	$28.17 - $59.01 $1.05 Million - $2.21 Million	37,440 Added 16.7%	261,602 $15.4 Million
Q2 2022 Aug 12, 2022	SELL	$22.39 - $38.94 $54,698 - $95,130	-2,443 Reduced 1.08%	224,162 $6.33 Million
Q1 2022 May 13, 2022	SELL	$30.13 - $50.0 $108,317 - $179,750	-3,595 Reduced 1.56%	226,605 $8.56 Million
Q4 2021 Feb 08, 2022	BUY	$22.28 - $39.54 $2.88 Million - $5.11 Million	129,174 Added 127.86%	230,200 $9.1 Million
Q3 2021 Nov 15, 2021	SELL	$20.89 - $26.96 $202,883 - $261,835	-9,712 Reduced 8.77%	101,026 $2.4 Million
Q2 2021 Aug 13, 2021	BUY	$16.8 - $29.65 $1.86 Million - $3.28 Million	110,738 New	110,738 $2.72 Million

29.6K

Ticker RXDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,904,100
Description
Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial...

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

Stay updated on Northern Trust Corp with notifications on news.